Preview

Experimental and Clinical Gastroenterology

Advanced search

Features of the course of irritable bowel syndrome in overweight and obese people

https://doi.org/10.31146/1682-8658-ecg-218-10-48-56

Abstract

The aim of the study: to study the characteristics of the course of irritable bowel syndrome (IBS), associated with overweight and obesity, to optimize the management of this group of patients. Material and methods. An open-label cross-sectional study was performed including 175 participants aged 18 to 44 years (mean age 30.06 ± 6.15 years). Group 1 included 100 patients with IBS aged 18 to 44 years (mean age 30.63 ± 6.37 years, BMI 25.88 ± 6.28 kg/m2). In group 1, subgroup 1A included 50 people with IBS associated with overweight or obesity. Subgroup 1B included 50 IBS patients with normal weight. Group 2 included 75 people who did not suffer from IBS, aged from 19 to 43 years (mean age 29.31 ± 5.81 years, BMI 27.80 ± 6.20 kg/m2). Subgroup 2A included 50 participants who did not suffer from IBS and were overweight or obese. Subgroup 2B included 25 apparently healthy participants. The presence and severity of IBS symptoms were assessed using a 10-point scale. The severity of gastrointestinal symptoms, the presence of anxiety and depression, the level of specific anxiety, quality of life and eating habits were assessed using verified questionnaires. All participants underwent a study of the levels of leptin and adiponectin in the blood serum and zonulin in the feces. Results. The characteristic clinical stigmas in patients suffering from IBS associated with overweight and obesity are described: IBS with a predominance of constipation, severe course of the disease, high incidence of signs of depressive and anxiety disorders, special eating habits characterized by the predominance of flour, sweet, fatty and salty foods in the diet food, severe disturbances in the permeability of the intestinal epithelial barrier. High concentrations of leptin and low levels of adiponectin in the blood serum of such patients may play a significant role in the formation of IBS symptoms. Conclusion. The results obtained open up opportunities for research into the pathogenetic mechanisms of the formation of IBS in people with overweight and obesity, as well as modification of existing treatment regimens for patients with IBS.

About the Authors

M. M. Fedorin
Omsk State Medical University
Russian Federation


M. A. Livzan
Omsk State Medical University
Russian Federation


O. V. Gaus
Omsk State Medical University
Russian Federation


References

1. Ivashkin V. T., Shelygin Yu.A., Baranskaya Y. K., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) doi: 10.22416/1382-4376-2017-27-5-76-93.@@ Ивашкин В. Т., Шелыгин Ю. А., Баранская Е. К., и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76-93. doi: 10.22416/1382-4376-2017-27-5-76-93.

2. Aasbrenn M., Høgestøl I., Eribe I., Kristinsson J., Lydersen S., Mala T., Farup P. G. Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. BMC Obesity. 2017;4:22. doi: 10.1186/s40608-017-0159-z.

3. Fedorin М. М., Gaus O. V., Livzan M. A., Sukhanova S. A. Typical dietary habits and elevated intestinal permeability in people with excess body weight and IBS. Experimental and Clinical Gastroenterology. 2021;190(6):50-56. (in Russ.) doi: 10.31146/1682-8658-ecg-190-6-50-56.@@ Федорин М. М., Гаус О. В., Ливзан М. А., Суханова С. А. Лица с избыточной массой тела и СРК имеют характерные пищевые привычки и повышенный уровень кишечной проницаемости. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):50-56.doi: 10.31146/1682-8658-ecg-190-6-50-56.

4. Svedlund J., Sjödin I., Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988 Feb;33(2):129-34. doi: 10.1007/BF01535722.

5. Cho H. S., Park J. M., Lim C. H. et al. Anxiety, depression and quality of life in patients with irritable bowel syndrome. Gut Liver. 2011;5(1):29-36. doi: 10.5009/gnl.2011.5.1.29.

6. Labus J. S., Mayer E. A., Chang L. et al. The central role of gastrointestinal specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med. 2007Jan;69(1):89-98. doi: 10.1097/PSY.0b013e31802e2f24.

7. Ware J. E. SF-36 health survey update. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9. doi: 10.1097/00007632-200012150-00008.

8. Drossman, D. A., Patrick, D. L., Whitehead, W. E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. The American journal of gastroenterology. 2000;95(4):999-1007. doi: 10.1111/j.1572-0241.2000.01941.x.

9. Erofeev Yu.V., Bokdireva M. S., Turchaninov D. V. et al. [Organization and methodology of conducting sociological studies of the health of the rural population for information support of the system of social and hygienic monitoring]. Omsk. 2004, 52 P. (in Russ.)@@ Ерофеев Ю. В., Болдырева М. С., Турчанинов Д. В. и др. Организация и методика проведения социологических исследований здоровья сельского населения для информационного обеспечения системы социально-гигиенического мониторинга: Метод. рекомендации. Омск. 2004, С. 52.

10. Rohm T. V., Meier D. T., Olefsky J. M., Donath M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022Jan11;55(1):31-55. doi: 10.1016/j.immuni.2021.12.013.

11. He J., Zhang P., Shen L. et al. Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism.Int J Mol Sci. 2020;21(17):6356. doi: 10.3390/ijms21176356.

12. Litwin M., Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol. 2021Apr;36(4):825-837. doi: 10.1007/s00467-020-04579-3.

13. Koutoukidis D. A., Jebb S. A., Zimmerman M. et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. Gut Microbes. 2022;14(1):2020068. doi: 10.1080/19490976.2021.2020068.

14. Matoshina IV, Fedorin MM, Livzan MA, Mozgovoy SI. Resistance of the esophageal mucosa in patients with GERD: the dialogue between clinician and pathologist. Effektivnaya farmakoterapiya. 2021;17(4):34-39. (In Russ.) doi: 10.33978/2307-3586-2021-17-4-34-39.@@ Матошина И. В., Федорин М. М., Ливзан М. А., Мозговой С. И. Резистентность слизистой оболочки пищевода у больных ГЭРБ. Диалог клинициста и морфолога. Эффективная фармакотерапия. 2021; 17(4): 34-39. doi: 10.33978/2307-3586-2021-17-4-34-39.

15. Ridlon J. M., Harris S. C., Bhowmik S. et al. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22-39. doi: 10.1080/19490976.2015.1127483.

16. Anstee Q. M., Day C. P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-1109. doi: 10.1016/j.jhep.2012.04.041.

17. Zhang M., Liu J., Li C. et al. Functional Fiber Reduces Mice Obesity by Regulating Intestinal Microbiota. Nutrients. 2022Jun28;14(13):2676. doi: 10.3390/nu14132676.


Review

For citations:


Fedorin M.M., Livzan M.A., Gaus O.V. Features of the course of irritable bowel syndrome in overweight and obese people. Experimental and Clinical Gastroenterology. 2023;(10):48-56. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-218-10-48-56

Views: 153


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)